Facial acneiform rash associated with sorafenib

Fleta-Asín, Beatriz; Vañó‐Galván, Sergio; Ledo-Rodríguez, Alejandro; Truchuelo-Díez, M.T.; Jaén‐Olasolo, Pedro

doi:10.5070/d34rg64357

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Skin reactions are commonly induced by multikinase inhibitors, but acneiform eruptions are rare. Several case reports have described the development of papules and pustules on the patient's face and upper trunk during treatment 24 . Cutaneous reaction is typical with the use of mTOR inhibitors and usually manifests as acneiform dermatitis 12 .…”

Section: Resultsmentioning

confidence: 99%

“…Several case reports have described the development of papules and pustules on the patient's face and upper trunk during treatment. 24 Cutaneous reaction is typical with the use of mTOR inhibitors and usually manifests as acneiform dermatitis. 12 Several clinical trials also reported acneiform eruption as cutaneous adverse events associated with the use of PD-1 inhibitors 25 and CTLA-4 inhibitors.…”

Section: Acneiform Eruptions With Targeted Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review

Cheng

Wang

2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Various biologic agents targeting specific molecules present new treatment options for various tumors. Acneiform eruption is a very common skin reaction to these agents. Although not life‐threatening, acneiform eruption can affect patients' emotional and social lives. In very exceptional cases, it can lead to cancer therapy interruption. Aims The aim of this study was to review the incidence rate, clinical characteristics, pathogenesis, and current management of acneiform eruption induced by molecularly targeted agents. Methods This review was carried out through PubMed, Embase, and Cochrane searching terms ‘acneiform eruption’, ‘papulopustular eruption’ or ‘acne‐like rash’ and ‘skin toxicity’, ‘cutaneous toxicity’, ‘skin reactions’, ‘dermatological toxicities’, ‘target therapy,’ or ‘drug therapy’. Results Of the 73 articles matched our search terms, 61 were original articles and 12 were case reports or case series. Acneiform eruption is most commonly observed in patients treated with epidermal growth factor receptor inhibitors and mitogen‐activated protein kinase inhibitors. Typical lesions consist of erythematous papules and pustules without comedones, accompanying with burning, pruritus, or xerosis. The pathogenesis involves inflammation and abnormalities of the follicular epithelium, where a disorder in EGFR signaling plays a key role. The treatment of acneiform eruption depends on the severity of the rash. Conclusions Early recognition and effective management of this cutaneous adverse reaction can prevent unnecessary reduction and discontinuation of drug use and improve patient survival and quality of life. Close collaboration between oncologists and dermatologists is important to optimize therapy and improve patient survival.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Acneiform Eruptions With Targeted Agentsmentioning

confidence: 99%

Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review

Cheng

Wang

2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0

Chen

Acharya

Setser³

2013

Dermatologic Principles and Practice in Oncology

View full text Add to dashboard Cite

Sorafenib-Associated Facial Acneiform Eruption

Cohen

2014

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionSorafenib is an oral multikinase inhibitor that targets tumor cell angiogenesis and proliferation. Drug-associated cutaneous adverse events, such as alopecia and hand–foot skin reaction, occur frequently. Sorafenib-related side effects affecting hair, nails, and skin are summarized and the characteristics of sorafenib-treated patients who developed acneiform facial lesions are reviewed to present the clinical features of these individuals.Case ReportA man with sorafenib-associated facial acneiform lesions mimicking those of chloracne is described.DiscussionPubMed was used to search the following terms, separately and in combination: acne, acneiform eruption, chloracne, cutaneous adverse events, hepatocellular carcinoma, renal cell carcinoma, skin side effects, and sorafenib. Inclusion criteria for selecting papers to be reviewed included case reports and studies that described cutaneous and mucosal adverse side effects associated with sorafenib. All papers fulfilling inclusion criteria were reviewed and relevant manuscripts, along with their reference citations, were evaluated. Five patients—a woman with liver epithelioid hemangioendothelioma, three men with metastatic renal cell carcinoma, and a man with hepatocellular carcinoma—have developed sorafenib-associated facial acneiform eruption. The eruption typically occurred after 4 weeks of treatment at a dose of 400 mg twice daily. The lesions presented as either papules and pustules (2 patients) or, similar in appearance and distribution to chloracne, only open and closed comedones (3 patients). The sorafenib-associated facial acneiform eruption partially improved after initiating topical antibiotics, keratolytics, and/or retinoids; however, progressive improvement or resolution occurred after lowering the daily dose or discontinuation of sorafenib.ConclusionsSorafenib-associated facial acneiform eruption is a rarely occurring cutaneous adverse event that has only been observed in five individuals. The skin lesions usually presented after 4 weeks of sorafenib (at a dose of 400 mg twice daily) treatment. The morphology and distribution of the lesions mimicked those of chloracne in three of the patients. Two of the patients also had other drug-related skin side effects. Topical acne-directed therapy was only partially effective in clearing the lesions; lowering the dose or discontinuation of sorafenib resulted in progressive improvement or resolution of the facial acneiform eruption.Electronic supplementary materialThe online version of this article (doi:10.1007/s13555-014-0067-9) contains supplementary material, which is available to authorized users.

show abstract

Facial acneiform rash associated with sorafenib

Cited by 10 publications

References 0 publications

Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review

Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review

Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0

Sorafenib-Associated Facial Acneiform Eruption

Contact Info

Product

Resources

About